Ty nt

Have ty nt matchless

In addition to his chemical endeavors he has been very active during his whole career in furthering the cause of chemistry not only in Germany but also abroad. He has served and is still serving on many boards and councils. To name a few: Heisenberg-stipend of the German Research Council, Inorganic Chemistry Section of the DFG, Committee for the Max-Planck Research Prize. In recognition of his well-regarded, excellent research Karl Wieghardt receives constant and numerous invitations to participate in national and international conferences.

He is a gifted lecturer. In 2000 he delivered the prestigious E. Swift lecture at Cal Tech, Ty nt. He has been awarded the Wilhelm Klemm Prize of the German Chemical Society (2000), the John C. Bailar Medal healthcare professional the University of Illinois (2000) and the Centenary Medal of the Royal Society of Chemistry (London) (2002) as recognition of his research in modern inorganic chemistry.

The training of PhD students and ty nt associates, who have had the privilege of being associated with his laboratory, is one of his most important contributions ty nt inorganic chemistry.

He has already supervised 75 Ph. Theses and ty nt the author of about 370 leading-edge research papers. Editorial xxi Together with many students, friends and colleagues, who are contributing to this special issue dedicated to Karl Wieghardt, along with many other nonparticipants in this volume, I would like to ty nt our sincere thanks for all ty nt did in the interest of chemistry, for his personal interest and for the good time we had and our further associations with him.

It is ty nt great pleasure to participate in an activity that honors Karl Wieghardt for his accomplishments and contributions to inorganic chemistry. Our partners will collect data and use cookies for ad personalization and measurement. Learn how we and our ad partner Google, collect and use data.

Journal of Organometallic Chemistry 694 (21), ty nt, 200960Anticancer activity, DNA-binding and DNA-denaturing aptitude of palladium(II) dithiocarbamatesZR Muhammad Kashif Amir, Shahan Zeb Khan, Faisal Hayat, Abbas Hassan, Ian S.

Journal of Organometallic Chemistry 717, 1-8, 201256New dimeric and supramolecular organotin (IV) complexes with a ty nt Schiff base as potential biocidal agentsS Shujah, Zia-ur-Rehman, N Muhammad, S Ali, N Khalid, MN TahirJournal of Organometallic Chemistry 696 (15), 2772-2781, 201154Organotin (IV) 4-methoxyphenylethanoates: Synthesis, spectroscopic characterization, X-ray structures and in vitro anticancer activity against human prostate cell lines (PC-3)N Muhammad, Zia-ur-Rehman, S Ali, A Meetsma, F ShaheenInorganica Chimica Acta 362 (8), 2842-2848, 200954New dimeric, trimeric and supramolecular organotin (IV) dithiocarboxylates: synthesis, structural characterization and biocidal activitiesZia-ur-Rehman, N Muhammad, S Ty nt, S Ali, IS Butler, A Meetsma.

Polyhedron 28 (16), 3439-3448, 200953Photoactivated platinum-based anticancer drugsZR Muhammad Imran, Wagma Ayub, Ian S. Journal of Coordination Chemistry 65 (6), 969-979, 201240New heteroleptic palladium(II) dithiocarbamates: synthesis, characterization, packing and anticancer activity against five different cancer cell linesZR Shahan Zeb Khan, Muhammad Kashif Amir, Imdad Ullah, Asma Ty nt, John M.

Applied Organometallic Chemistry 30, 392-398, 201636CdS nanocapsules and nanospheres as efficient solar light-driven photocatalysts for degradation of Congo red dyeZHS Azam Khan a, Zia-ur-Rehman, Muneeb-ur- Rehman, Rajwali Khan, Zulfiqar.

Journal of Organometallic Chemistry 741, 59-66, 201328. Analytical chemistry 87 (19), 9786-9794, 201528Regioselective formation of N-alkyl-3, 5-pyrazole derived ligands. A synthetic and computational studyV Montoya, J Pons, V Branchadell, J RosTetrahedron 61 (52), give, 200528Synthesis and characterisation of new N1-alkyl-3, 5-dipyridylpyrazole derived ligands.

Applied Geochemistry 115, 104562, 202016Palladium(II) and platinum(II) complexes with N1-hydroxyethyl-3,5-pyrazole derived ligandsJA Perez, V Montoya, JA Ayllon, M Font-Bardia, T Calvet, J PonsInorganica Chimica Acta 394, 21-30, 201316Determination and assessment ty nt the concentration limits to be used in SR-Can. Applied Geochemistry 112, 104479, 20209Redox processes in the safety case of deep geological repositories of radioactive wastes.

CatClay Final Scientific Report D 1, 20147. S83213Ali Yousaf,1 Shafida Abd Hamid,1 Noraslinda M Bunnori,1 AA Ishola2 1Kulliyyah of Science, 2Kulliyyah of Medicine, International Islamic University Malaysia, Bandar Indera Mahkota, Malaysia Abstract: Research on the therapeutic applications of calixarene derivatives is an emerging area of interest.

Due to their superior geometric shape, calixarenes can accommodate drug molecules by forming inclusion complexes. Controlled release of anticancer drugs by calixarenes might help in targeted chemotherapy. This review summarizes ty nt anticancer potential of the calixarenes and their drug loading properties. The potential use of calixarenes in chemoradiotherapy is also highlighted in brief. Keywords: cancer, chemotherapy, calixarenesChemotherapy occupies a pivotal position in the treatment of cancer, and its significance in terms of cure and regression of various types of cancer should not be underestimated.

As a result, healthy tissues, such as bone marrow, the gastrointestinal mucosa, hair follicles, and skin are directly affected by a chemotherapeutic regimen, even with preliminary chemotherapy. These side ty nt lead to various complications during and after treatment. However, all available and upcoming anticancer drugs face the same problem of non-selectivity.

Therefore, from the last three decades, new trends have been developed for targeted chemotherapy, ie, introduction of nanotechnology, use of cancer biomarkers, and ty nt of physical parameters (eg, pH, temperature, light) in the treatment of cancer. Among the synthetic macromolecules, crown ether, cyclodextrin, and calixarenes and their derivatives are of great significance. Ty nt addition to their unique physicochemical properties, they also serve as hosts that can encapsulate many types of guests.

Calixarene is a cyclic oligomer that can be synthesized by the reaction of phenol with formaldehyde in the presence of a catalytic amount of a strong base or acid. The flexible nature of the basic moiety and ty nt modification of their basic core and rims make these cyclic oligomers ty nt for use as drugs and drug carriers.

The anticancer activity of calixarene-based compounds has been investigated by several research groups. When compared with a chemotherapeutic agent, carboplatin, the newly synthesized ty nt showed better activity against non-small cell lung cancer, hepatocellular cancer, and breast cancer. By using colorimetric cytotoxicity tests, its median inhibitory concentration (IC50) in a lung cancer cell line was found to be 2.

To date, the US clinical trials database shows only one Phase I study of OTX008, a calixarene-based compound and galectin-1 inhibitor ty nt potential antiangiogenic and antineoplastic activity. The study has been ongoing since 2012, with no results reported as yet. Enzyme inhibition is a common mode ty nt action for some chemotherapeutic drugs.

Several ty nt derivatives have been studied and reported to act as potent enzyme inhibitors. The same group also reported that hydroxymethylphosphonic acid calixarenes inhibited glutathione-S-transferase, a key enzyme in the xenobiotic detoxification process in cells, thereby contributing toward the multidrug resistance observed in many types of tumors. Survival of tumor cells ty nt on a sufficient supply of nutrients and oxygen, and waste removal via blood vessels.

Hence, the presence of new blood vessels within the tumor formulary essential for their growth. Platelet-derived growth factor (PDGF) plays an important role in angiogenesis by interaction with the PDGF receptor. Later, in vivo studies demonstrated that a polycation-modified member of these compounds had improved efficacy against MA-148 ovarian cancer cells and B16 mouse melanoma cells.

Likewise, antibody-based chemotherapeutic ty nt potently target host immunity components or receptors that enhance proliferation, survival, dedifferentiation, and migration of cancer cells. They focused on MUC-1 protein, overexpression of which is associated with ty nt epithelial carcinomas.



23.12.2019 in 07:15 Mulabar:
You the talented person

24.12.2019 in 05:59 Yozshulkree:
You were visited with simply excellent idea

24.12.2019 in 11:39 Goltikasa:
I apologise, but, in my opinion, you are not right. I am assured. I can defend the position. Write to me in PM, we will talk.

28.12.2019 in 13:19 Meztile:
Bravo, you were visited with simply brilliant idea

31.12.2019 in 21:28 Kaziktilar:
Between us speaking, in my opinion, it is obvious. I recommend to look for the answer to your question in google.com